# Crisantaspase (recombinant Erwinia asparaginase)

Source: https://onco.cc/drugs/crisantaspase/  
OnCo record `crisantaspase` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Enrylaze is a replacement asparaginase for children and adults with acute lymphoblastic leukaemia or lymphoblastic lymphoma whose bodies have reacted against, or quietly neutralised, the usual E. coli asparaginase. It keeps the asparagine-starving part of their chemotherapy going.

## Summary

Crisantaspase (Enrylaze) is authorised in the EU since 15 September 2023 (CHMP opinion 20 July 2023; marketing authorisation holder Jazz Pharmaceuticals Ireland Limited) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukaemia and lymphoblastic lymphoma in adults and children from one month of age who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. It is under additional monitoring in the EU. The class record `asparaginase` covers pegaspargase, calaspargase pegol and the native Erwinia enzyme; this record is the recombinant Erwinia product.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-22
- Also known as: crisantaspase; Enrylaze; recombinant Erwinia chrysanthemi asparaginase; JZP-458
- Tags: ema-register
- Brand: Enrylaze
- Modality: Enzyme therapy (recombinant asparaginase)
- Mechanism: Asparaginase enzyme that depletes circulating asparagine, on which lymphoblasts depend; the recombinant Erwinia enzyme is given to patients who have reacted to or silently inactivated E. coli-derived asparaginase (indication wording, EMA).
- Approvals: EU 2023: ALL and lymphoblastic lymphoma, in a multi-agent regimen, after hypersensitivity or silent inactivation to E. coli-derived asparaginase (adults and children from 1 month)

## Sources

- EMA: Enrylaze (EPAR): https://www.ema.europa.eu/en/medicines/human/EPAR/enrylaze

## Connected records

- drugs: [Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)](https://onco.cc/drugs/asparaginase/), [Eryaspase](https://onco.cc/drugs/eryaspase/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)](https://onco.cc/cancers/all-paediatric-high-risk/), [Standard-risk B-cell acute lymphoblastic leukaemia in children](https://onco.cc/cancers/all-paediatric-standard-risk/)
- companies: [Jazz Pharmaceuticals](https://onco.cc/companies/jazz/)

---
JSON: https://onco.cc/api/v1/entities/crisantaspase.json